TBD Pharmatech’s ongoing expansion of its pilot-scale capabilities under the “Small-molecule Novel Drug Ingredients Lab” project (RE.5.04.23-0268, 01.01.2025–30.06.2025) continues with a major investment in key process equipment.
Funded by Enterprise Estonia (EAS), this recent procurement includes advanced reactor systems (1000L, 630L, 400L, 250L, 160L), high-pressure and vacuum equipment, centrifuges, nutsche filters, and distillation units — all essential for scaling up the synthesis, purification, and drying of small-molecule active pharmaceutical ingredients (APIs).
These additions enable TBD Pharmatech to:
-
Conduct multistep reactions and crystallizations at pilot scale
-
Perform solid-liquid separations under pressure or vacuum
-
Carry out hydrogenations and high-temperature syntheses
-
Execute deep vacuum distillation and solvent recovery
-
Simulate full production workflows for process development and scale-up
With this infrastructure, TBD Pharmatech is well-positioned to support both preclinical R&D and technology transfer to GMP manufacturing, reinforcing our commitment to offering high-quality development services for novel therapeutic molecules.
Ravimainete arendaja ja tootja, mis pakub peenkeemia lahendusi farmaatsia- ja biotehnoloogia ettevõttetele.